REToma: a cancer subtype with a shared driver oncogene.
Animals
Carcinogenesis
/ drug effects
Clinical Trials as Topic
Disease Models, Animal
Humans
Mice
Mice, Transgenic
Mutation
Neoplasms
/ drug therapy
Oncogene Proteins, Fusion
/ antagonists & inhibitors
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins c-ret
/ antagonists & inhibitors
Pyrazoles
/ pharmacology
Pyridines
/ pharmacology
Pyrimidines
/ pharmacology
Journal
Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055
Informations de publication
Date de publication:
22 04 2020
22 04 2020
Historique:
received:
30
08
2019
revised:
17
10
2019
accepted:
07
11
2019
pubmed:
12
11
2019
medline:
1
9
2020
entrez:
12
11
2019
Statut:
ppublish
Résumé
RET (REarranged during Transfection), which encodes a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor, plays a role as driver oncogene in a variety of human cancers. Fusion of RET with several partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic and breast cancers, and tyrosine kinase inhibitors (TKIs) for RET (particularly RET-specific inhibitors) show promising therapeutic effects against such cancers. Oncogenic mutations within the extracellular cysteine-rich and intracellular kinase domains of RET drive medullary thyroid carcinogenesis; the same mutations are also observed in a small subset of diverse cancers such as lung, colorectal and breast cancers. Considering the oncogenic nature of RET mutants, lung, colorectal and breast cancers are predicted to respond to RET TKIs in a manner similar to medullary thyroid cancer. In summary, cancers carrying oncogenic RET alterations as a driver mutation could be collectively termed 'REToma' and treated with RET TKIs in a tissue-agnostic manner.
Identifiants
pubmed: 31711124
pii: 5621476
doi: 10.1093/carcin/bgz184
doi:
Substances chimiques
Oncogene Proteins, Fusion
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyridines
0
Pyrimidines
0
pralsetinib
0
selpercatinib
CEGM9YBNGD
Proto-Oncogene Proteins c-ret
EC 2.7.10.1
RET protein, human
EC 2.7.10.1
Ret protein, mouse
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-129Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.